

TENNESSEE GENERAL ASSEMBLY
FISCAL REVIEW COMMITTEE



FISCAL NOTE

SB 518 - HB 1222

February 14, 2017

SUMMARY OF BILL: Removes the Board of Pharmacy's (Board) oversight of certain facilities that distribute dialysate drugs or devices necessary to perform home peritoneal kidney dialysis to patients with end state renal disease if certain criteria are met. Authorizes the Board to exempt additional drugs for peritoneal dialysis from its oversight by rules.

ESTIMATED FISCAL IMPACT:

NOT SIGNIFICANT

Assumptions:

- The Board can update any rule change during a regularly-scheduled board meeting; therefore, any fiscal impact is estimated to be not significant.
- Based on information provided by the Department of Health, it is estimated the proposed legislation will have no impact on Board licensing fees or expenditures.
- The Board will retain oversight through licensing and regulation of all other drugs for peritoneal dialysis except dialysate drugs.
- Pursuant to Tenn. Code Ann. § 4-29-121, all health related boards are required to be self-supporting over a two-year period. The Board of Pharmacy had an annual surplus of \$284,085 in FY14-15, an annual surplus of \$885,058 in FY15-16, and a cumulative reserve balance of \$2,236,772 on June 30, 2016.

CERTIFICATION:

The information contained herein is true and correct to the best of my knowledge.

A handwritten signature in blue ink that reads "Krista M. Lee".

Krista M. Lee, Executive Director

/jem